Trial Profile
Effect of Once-Weekly Teriparatide for Bisphosphonate-Resisitance Glucocorticoid-Induced Osteoporosis (TeriGo)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 11 Apr 2019
Price :
$35
*
At a glance
- Drugs Teriparatide (Primary) ; Bisphosphonates
- Indications Osteoporosis
- Focus Therapeutic Use
- Acronyms TeriGo
- 09 Apr 2019 Status changed from recruiting to discontinued.
- 25 Oct 2016 Status changed from not yet recruiting to recruiting.
- 19 May 2016 New trial record